Literature DB >> 2066187

HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites.

V Mattijssen1, P H De Mulder, L Schalkwijk, J J Manni, B Van 't Hof-Grootenboer, D J Ruiter.   

Abstract

HLA class I and II antigen expression in routinely processed head and neck squamous cell carcinoma (HNSCC) primary lesions was evaluated. Paraffin embedded samples from 66 squamous cell carcinomas and 7 verrucous carcinomas were studied immunohistochemically using recently developed anti-HLA class I monoclonal antibodies (MAbs) HC10 and HCA2, and anti-HLA-DR rabbit serum. Percent stained tumor cells were scored in 1 of 5 categories. The scores of 40 tumors were compared to the staining results obtained on frozen sections of the corresponding lesions, including those of the anti-class I MAb W6/32. High percentage-matched scores for paraffin and frozen sections were obtained, with HC10 vs. HC10, HC10 vs. W6/32, and anti-HLA-DR vs. anti-HLA-DR showing the best correlations. In the squamous cell carcinomas HLA class I expression was high (i.e., in 49/66 lesions more than 50% cells were stained), and correlated with the degree of differentiation, and inversely with the modified Jakobsson score. HLA class II expression (more than 5% cells stained) was found in 21/66 tumors and correlated inversely with the degree of differentiation. All verrucous carcinomas exhibited very high HLA class I expression, whereas class II was locally expressed in 5/7 lesions. Comparison of 4 subsites of HNSCC showed that carcinomas of the oral cavity had the highest HLA class I expression. This suggests susceptibility to CD8+ T cells, and together with the well developed submucosal lymphoid tissue, makes the oral cavity carcinomas probably well suited for local immunotherapeutic approaches in HNSCC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066187     DOI: 10.1002/ijc.2910470719

Source DB:  PubMed          Journal:  Int J Cancer Suppl        ISSN: 0898-6924


  8 in total

Review 1.  Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance.

Authors:  Robert L Ferris; Jennifer L Hunt; Soldano Ferrone
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  The role of major histocompatibility complex expression on head and neck cancer cells in the induction of autologous cytotoxic T lymphocytes.

Authors:  K Chikamatsu; M Eura; H Matsuoka; H Murakami; T Fukiage; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

3.  An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.

Authors:  A R Vora; S Rodgers; A J Parker; R Start; R C Rees; A K Murray
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  In vivo Downregulation of MHC Class I Molecules by HCMV Occurs During All Phases of Viral Replication but Is Not Always Complete.

Authors:  Florin Gabor; Gerhard Jahn; Daniel D Sedmak; Christian Sinzger
Journal:  Front Cell Infect Microbiol       Date:  2020-06-12       Impact factor: 5.293

Review 5.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Authors:  Karthik Dhatchinamoorthy; Jeff D Colbert; Kenneth L Rock
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

6.  Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma.

Authors:  Y Mizukami; K Kono; T Maruyama; M Watanabe; Y Kawaguchi; K Kamimura; H Fujii
Journal:  Br J Cancer       Date:  2008-10-07       Impact factor: 7.640

Review 7.  Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma.

Authors:  Darrin V Bann; Daniel G Deschler; Neerav Goyal
Journal:  Cancers (Basel)       Date:  2016-09-22       Impact factor: 6.639

8.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.